Analyst Jack Allen of Robert W. Baird maintained a Buy rating on Arcellx Inc (ACLX – Research Report), retaining the price target of $77.00.
Jack Allen has given his Buy rating due to a combination of factors surrounding Arcellx Inc.’s promising developments in their clinical-stage CAR-T cell therapies, particularly for treating multiple myeloma. His optimism is rooted in the company’s recent announcement of the iMMagine-3 study design, which he believes positions the company’s leading therapy, anito-cel, competitively for rapid commercialization. Allen notes that the thoughtful design of the iMMagine-3 trial aims to ensure broad commercial access in the lucrative second-line multiple myeloma market, should the results be positive.
Moreover, he highlights the strategic advantage offered by the study’s inclusive criteria, which could allow anito-cel to target a significant portion of the patient population, including those not refractory to lenalidomide—a requirement for other BCMA CAR-T therapies. Additionally, Allen anticipates that the forthcoming iMMagine-1 study results will be a critical clinical catalyst for Arcellx. This data is expected to not only support initial regulatory approvals but also to provide a favorable comparison to existing therapies, potentially solidifying the company’s position in the market.
According to TipRanks, Allen is an analyst with an average return of -14.1% and a 30.34% success rate. Allen covers the Healthcare sector, focusing on stocks such as Lineage Therap, Bluebird Bio, and Arcellx Inc.
TipRanks tracks over 100,000 company insiders, identifying the select few who excel in timing their transactions. By upgrading to TipRanks Premium, you will gain access to this exclusive data and discover crucial insights to guide your investment decisions. Begin your TipRanks Premium journey today.
Arcellx Inc (ACLX) Company Description:
Arcellx Inc is a clinical-stage biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases.
